XBiotech (XBIT) Competitors $2.83 -0.13 (-4.39%) Closing price 07/11/2025 04:00 PM EasternExtended Trading$2.84 +0.01 (+0.35%) As of 07/11/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIT vs. TERN, HUMA, PRTA, HRTX, AMRN, PRME, SNDL, AQST, CTOR, and OLMAShould you be buying XBiotech stock or one of its competitors? The main competitors of XBiotech include Terns Pharmaceuticals (TERN), Humacyte (HUMA), Prothena (PRTA), Heron Therapeutics (HRTX), Amarin (AMRN), Prime Medicine (PRME), SNDL (SNDL), Aquestive Therapeutics (AQST), Citius Oncology (CTOR), and Olema Pharmaceuticals (OLMA). These companies are all part of the "pharmaceutical products" industry. XBiotech vs. Its Competitors Terns Pharmaceuticals Humacyte Prothena Heron Therapeutics Amarin Prime Medicine SNDL Aquestive Therapeutics Citius Oncology Olema Pharmaceuticals XBiotech (NASDAQ:XBIT) and Terns Pharmaceuticals (NASDAQ:TERN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation. Do institutionals and insiders have more ownership in XBIT or TERN? 55.7% of XBiotech shares are held by institutional investors. Comparatively, 98.3% of Terns Pharmaceuticals shares are held by institutional investors. 33.1% of XBiotech shares are held by insiders. Comparatively, 1.5% of Terns Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer XBIT or TERN? Terns Pharmaceuticals has a consensus price target of $15.63, indicating a potential upside of 218.88%. Given Terns Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Terns Pharmaceuticals is more favorable than XBiotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Terns Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has more volatility & risk, XBIT or TERN? XBiotech has a beta of 0.98, indicating that its share price is 2% less volatile than the S&P 500. Comparatively, Terns Pharmaceuticals has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500. Which has better earnings & valuation, XBIT or TERN? XBiotech has higher revenue and earnings than Terns Pharmaceuticals. Terns Pharmaceuticals is trading at a lower price-to-earnings ratio than XBiotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXBiotech$4.01M21.52-$38.53M-$1.29-2.19Terns PharmaceuticalsN/AN/A-$88.85M-$1.09-4.50 Is XBIT or TERN more profitable? XBiotech's return on equity of -21.14% beat Terns Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets XBiotechN/A -21.14% -19.55% Terns Pharmaceuticals N/A -28.81%-27.55% Does the media refer more to XBIT or TERN? In the previous week, Terns Pharmaceuticals had 2 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Terns Pharmaceuticals and 1 mentions for XBiotech. XBiotech's average media sentiment score of 1.24 beat Terns Pharmaceuticals' score of 0.82 indicating that XBiotech is being referred to more favorably in the media. Company Overall Sentiment XBiotech Positive Terns Pharmaceuticals Positive SummaryXBiotech beats Terns Pharmaceuticals on 8 of the 14 factors compared between the two stocks. Get XBiotech News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIT vs. The Competition Export to ExcelMetricXBiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$90.24M$2.98B$5.60B$9.10BDividend YieldN/A2.39%5.24%4.00%P/E Ratio-2.1920.5827.9620.25Price / Sales21.52291.32429.2099.14Price / CashN/A42.8637.4658.16Price / Book0.477.638.045.49Net Income-$38.53M-$55.05M$3.18B$250.27M7 Day Performance-10.58%8.39%3.63%4.75%1 Month Performance2.54%5.35%4.04%7.64%1 Year Performance-54.50%1.95%29.56%16.34% XBiotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBITXBiotech1.8575 of 5 stars$2.83-4.4%N/A-57.5%$90.24M$4.01M-2.19100Positive NewsTERNTerns Pharmaceuticals3.9146 of 5 stars$3.73-2.6%$15.63+318.9%-41.2%$334.50MN/A-3.4240HUMAHumacyte2.2032 of 5 stars$2.09-1.4%$11.71+460.5%-64.2%$328.85M$1.57M-3.03150Analyst ForecastPRTAProthena3.5751 of 5 stars$6.07-0.2%$31.50+418.9%-71.4%$327.27M$135.16M-2.92130HRTXHeron Therapeutics3.6841 of 5 stars$2.07-3.3%$5.00+141.5%-34.1%$326.49M$144.29M-34.50300Positive NewsAMRNAmarin0.4384 of 5 stars$16.22+3.2%$12.00-26.0%+13.5%$325.31M$228.61M-4.46360Positive NewsHigh Trading VolumePRMEPrime Medicine3.9289 of 5 stars$2.47+2.1%$10.08+308.2%-27.5%$324.30M$3.85M-1.20234Positive NewsHigh Trading VolumeSNDLSNDL3.0542 of 5 stars$1.21-1.6%$3.63+199.6%-36.2%$323.21M$671.81M-4.172,516News CoverageAQSTAquestive Therapeutics1.7263 of 5 stars$3.31+1.8%$10.14+206.4%+46.9%$322.82M$57.56M-5.61160CTORCitius Oncology0.3663 of 5 stars$4.35-3.3%$3.00-31.0%N/A$321.99MN/A0.00N/ANews CoverageGap DownOLMAOlema Pharmaceuticals2.4236 of 5 stars$4.26-7.8%$24.50+475.1%-62.8%$316.11MN/A-2.1270Positive News Related Companies and Tools Related Companies TERN Competitors HUMA Competitors PRTA Competitors HRTX Competitors AMRN Competitors PRME Competitors SNDL Competitors AQST Competitors CTOR Competitors OLMA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIT) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored"I'm risking my reputation on this"Most people think you need thousands to profit from crypto. But this free book exposes how even small inves...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XBiotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share XBiotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XBIT Stock Alerts